Skip to main content

Failure to Counsel Can Lead to Litigation

  • Chapter
  • First Online:
Medico-Legal Issues in Infectious Diseases

Part of the book series: Emerging Infectious Diseases of the 21st Century ((EIDC))

  • 541 Accesses

Abstract

Most senior physicians still in practice can recall their earlier experiences when patients were rarely informed about their disease, much less their medications. Most patients then (and still common in developing nations) were unaware of their diagnosis, names or types of medications and potential side effects. We have come a long way since then, but some patients still remain in the dark about their illnesses or medications. In the distant past, when physicians were held in high esteem and given unquestionable authority, treatment and investigations were ordered empirically without explanation or the patients’ input. Nowadays, the expectations are different and physicians are held accountable for making unilateral decisions. At present, in most developed countries, the approach to management of a patient’s condition is expected to be a joint venture between the physician and patient or family. This chapter will give case scenarios where the health care system (particularly physicians) have failed the patients by omission in providing adequate information and counselling.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wilson WR, Thompson RL, Wilkowske CJ, Washington JA 2nd, Giuliani ER, Geraci, JE (1980). Short-term therapy for streptococcal infective endocarditis: combined intramuscular administration of penicillin and streptomycin. JAMA 245:360–363.

    Article  Google Scholar 

  2. Sexton DJ, Tenebaum MJ, Wilson WR, Steckelberg JM, Tice AL, Gilbert D, Dismukes W, Drew RH, Durack DT, and the Endocarditis Treatment Consortium Group (1998). Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Clin Infect Dis 27:1470–1474.

    Article  PubMed  CAS  Google Scholar 

  3. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr., Bolger AF, Levison ME, Ferrieri R, Gerber MA, Tanl LY, Gewitz, MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch J, Takahshi M, Tambert KA, (2005). Infective endocarditis: diagnosis, antimicrobial therapy and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Disease Society of America. Circulation III:e394–e432, DOI:10.1161/Circulation AHA 105.165564.

    Article  Google Scholar 

  4. Tunkel AR, Kaufman BA (2005). Cerebrospinal shunt infections. In: (eds.) Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases, 6th Edition. Elsevier/Churchill/Livingstone, Philadelphia, p. 1126–1132.

    Google Scholar 

  5. Morrisette I, Gourdeau M, Francoeur J (1993). CSF shunt infections: a fifteen-year experience with emphasis on management and outcome. Can. J Neurol Sci 20:118–122.

    Google Scholar 

  6. Fong IW, Tomkins KB (1985). Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 7:604–612.

    Article  PubMed  CAS  Google Scholar 

  7. Fong IW (ed) (2009). Combination antimicrobial therapies. In: Emerging issues and controversies in infectious disease. Springer, New York, p. 337–377.

    Google Scholar 

  8. Pintado V, Cabellos C, Moreno S, Meseguer MA, Ayats J, Viladrich PF (2003). Enterococcal meningitis: a clinical study of 39 cases and review of the literature. Medicine; 82:346–364.

    Article  PubMed  Google Scholar 

  9. Chapman PH, Borges LF (1985). Shunt infections: prevention and treatment. Clin Neurosurg 32:652–664.

    PubMed  CAS  Google Scholar 

  10. Sweet RL, Gibbs RS (eds) (1985). Pelvic inflammatory disease. In: Infectious diseases of the female genital tract; Williams & Wilkins, p. 53–77.

    Google Scholar 

  11. Lipsky BA, Berendt AR, Deary HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C., Tan JS (2004). Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910.

    Article  PubMed  Google Scholar 

  12. Fong IW (1996). Management of diabetic foot infection: a position paper. Can J Infect Dis 7:361–365.

    Google Scholar 

  13. Whelton A (1982). Renal tubular transport and intrarenal aminoglycoside distribution. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc., New York, p. 191–221.

    Google Scholar 

  14. Smith TR, Smith CR (1982). Risk factors for aminoglycoside nephrotoxicity. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc., New York, p. 401–415.

    Google Scholar 

  15. Brummett RE, Fox KE (1982). Studies of aminoglycoside ototoxicity in animal models. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc., New York, p. 453–486.

    Google Scholar 

  16. Blendush CL (1982). Ototoxicity: clinical considerations and comparative information. In: (eds.) Whelan A, Neu HC. The aminoglycoside: microbial, classical use, and toxicology. Marcel Dekker, Inc, New York, p. 453–486.

    Google Scholar 

  17. Guiliunas P, Dominguez-Moreno M, Lazarus JM, Lowrie EG, Gottlieb MN, Merrill JP (1978). Vestibular toxicity of gentamicin. Arch Intern Med 138:1621–1624.

    Article  Google Scholar 

  18. Chambers HF (2005). Aminoglycosides. In: (eds) Brunton LL, Lozo JS, Parker KL Goodman and Gilman: The pharmacological basis of therapeutics, 11th Edition, McGraw-Hill, New York, p. 1155–1171.

    Google Scholar 

  19. Bitner-Glindzicz M, Rachman S (2007). Ototoxicity caused by aminoglycosides is severe and permanent in genetically susceptible people. BMJ 335:784–785.

    Article  PubMed  Google Scholar 

  20. Usami S, Abe S, Shinkawa H, Kimberling WJ (1998). Sensorineural hearing loss caused by mitochondrial DNA mutations: special reference to A1555G mutation. J Commun Disord 31:423–434.

    Article  PubMed  CAS  Google Scholar 

  21. Estivill X, Goven N, Barcelo F, Badenas C, Romero ER, Moral L, Scozzri R, D’Urbano L, Zevianni M, Torroni A (1998). Familial progressive sensorineural deafness is mainly due to mt DNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet 62:27–33.

    Article  PubMed  CAS  Google Scholar 

  22. Buchholtz K, Larsen CT, Hassager C, Bruun NE (2009). Severity of gentamicin’s nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis 48:65–71.

    Article  PubMed  Google Scholar 

  23. Cosgrove SE, Vigliani GA, Campion M, Fowler VG Jr, Abrutyn E, Corey R, Levine DP, Rupp M, Chambers HF. Karchmer AW, Boucher HW (2009). Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48:713–721.

    Article  PubMed  Google Scholar 

  24. Leibovici L, Vidal L, Paul M, (2009). Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 63:246–251.

    Article  PubMed  CAS  Google Scholar 

  25. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH, (1997). Once daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 39:677–686.

    Article  PubMed  CAS  Google Scholar 

  26. Reeves DS, MacGowan AP, (1993). Once-daily aminoglycoside dosing. Lancet 341:895–896.

    PubMed  CAS  Google Scholar 

  27. Berringer R, (2008). Aminoglycoside therapy balancing risk versus benefit. Risk identification for all physicians. Can Med Protect Assoc R10814E: www.cmpa-acpm.ca.edu.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I. W. Fong .

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Fong, I.W. (2011). Failure to Counsel Can Lead to Litigation. In: Medico-Legal Issues in Infectious Diseases. Emerging Infectious Diseases of the 21st Century. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8053-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-8053-3_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-8052-6

  • Online ISBN: 978-1-4419-8053-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics